Showing results (1571-1580 of 1,649) with videos related to
Sort By:
Pageof 165
Mechanisms of Development|February 13, 2016
The protein phosphatase 6 catalytic subunit (Ppp6c) is indispensable for proper post-implantation embryogenesisHonami Ogoh, Nobuhiro Tanuma, Yasuhisa Matsui, et al.Annals of Surgical Oncology|February 29, 2024
Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint InhibitorsKeisuke Kosumi, Yoshifumi Baba, Yoshihiro Hara, et al.The Journal of Dermatology|July 31, 2023
Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis studyYusuke Muto, Yumi Kambayashi, Hiroshi Kato, et al.Surgical Oncology|June 5, 2017
Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment eraMinoru Miyashita, Hiroshi Tada, Akihiko Suzuki, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 21, 2017
SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesisHirotaka Ishida, Atsuko Kasajima, Takashi Kamei, et al.BMC Cancer|December 19, 2025
Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective studyIssei Oi, Kohei Fujita, Takuma Imakita, et al.Cancer Management and Research|April 4, 2022
Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective StudyHiroo Imai, Ken Saijo, Keigo Komine, et al.Breast Cancer Research and Treatment|August 24, 2017
Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinomaKyoko Kikuchi, Keely May McNamara, Yasuhiro Miki, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2022
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLCRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.Journal for Immunotherapy of Cancer|June 29, 2026
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancerRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.Pageof 165